Best practical management of AD patients

Experience from Asia and Europe

Join the conversation with our faculty of international experts as they share their expertise on best practice for atopic dermatitis management, with insights on the latest scientific advances and treatment approaches

> NOVEMBER 2020 15:00 • 18:20 (UTC +8)

Sunday 29th

LIVE BROADCAST FROM National Taiwan University Hospital

CLICK HERE TO REGISTER



SANOFI GENZYME 🍞 REGENERON



Chaired by Professor Chia-Yu Chu

Department of Dermatology National Taiwan University Hospital

"This meeting will offer an opportunity to **exchange experience and knowledge** between participants. We will collaborate with our colleagues and the **experts from Europe and Asia**, and the session will cover both clinical and scientific aspects.

We will incorporate topics on **pathophysiology** of atopic dermatitis, recent evidence on non-systemic and systemic therapies, and comorbidities associated with AD.

We will focus on the **optimal management** under consideration of **skin of color** and **disease phenotype in the Asian population**. We will also share the **latest treatment guidelines and disease assessment** in this field."

TIME	ZONES
Copenhagen/Rome (UTC +1)	08:00 – 11:20
Dubai (UTC +4)	11:00 – 14:20
Beijing/Hong Kong/ Singapore/Taipei (UTC +8)	15:00 – 18:20

SANOFI GENZYME 🍞 🛛 REGENERON

Agenda



15:00 – 15:10	Welcome and introduction to the National Taiwan University Hospital Chia-Yu Chu
15:10 – 15:15	AD as a type 2 disease and its pathogenesis Narrated animation
15:15 – 15:20	The atopic march Jacob Thyssen
15:20 – 15:35	Atopic dermatitis comorbidities: AD as a systemic disease inc. case study Liang-Shiou Ou
15:35 – 15:50	Recent advances: Non-systemic therapies in AD Yu Yu
15:50 – 16:05	Recent advances: Systemic therapies in AD (biologics and small molecules) Jacob Thyssen
16:05 – 16:30	AD treatment guidelines and disease assessment: 2020 TDA consensus Jacob Thyssen, Yung-Tsu Cho, Chia-Yu Chu
16:30 – 16:45	Case discussions: systemic therapy in daily practice Yao Xu, Yu-Huei Huang
16:45 – 16:50	Break
16:50 – 17:05	Application of allergen-specific management in atopic dermatitis inc. case study Li-Chieh Wang
17:05 – 17:20	Atopic dermatitis in skin of color and in Asian populations inc. case study Mark Tang
17:20 – 17:35	Atopic dermatitis disease phenotypes and therapeutic implications Dr Po-Ju Lai
17:35 – 18:00	Case discussions: Complex AD cases with dupilumab Christina Wong, Mark Tang
18:00 – 18:15	Q&A Panel discussion
18:15 – 18:20	Close Chia-Yu Chu

Sanofi Genzyme and Regeneron are committed to providing resources to advance research in dermatology in areas of unmet medical needs among patients with poorly controlled moderate-to-severe atopic dermatitis.

 $\textcircled{\sc c}$ 2020 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. GZEMEA.AD. MAT-TW-2000985 Date of preparation:October 2020.